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Abstract
Background: As the African Programme for Onchocerciasis Control (APOC) matured into its 10
th year of ensuring
community involvement in mass annual treatment of onchocerciasis with ivermectin, there was recognition of a
need to study not only annual coverage of ivermectin in villages but also the compliance of individual villagers
with these annual treatments. This was based on the concern that while population coverage goals may be
achieved each year, there might be segments of the population who systematically are not complying with the
annual regimen, thus creating a reservoir of infection and threatening program gains.
Methods: A multi-site study in five APOC sponsored projects in Nigeria and Cameroon was undertaken to identify
the socio-demographic correlates of compliance with ivermectin treatment. A total of 8,480 villagers above 9 years
of age selected through a systematic random sampling from 101 communities were surveyed to ascertain their
levels of compliance, by adapting APOC’s standard household ivermectin survey form. Community leaders,
community directed distributors (CDDs) of ivermectin and health workers were interviewed with in-depth interview
guides, while focus group discussions were held with community members to help explain how socio-
demographic factors might affect compliance.
Results: Eight-year compliance ranged from 0 to 8 times with 42.9% taking ivermectin between 6-8 times annually
(high compliance). In bivariate analysis high compliance was positively associated with being male, over 24 years of
age, having been married, not being Christian, having little or no formal education and being in the ethnic
majority. These variables were also confirmed through regression analysis based on total times ivermectin was
taken over the period. While these factors explained only 8% of the overall variation in compliance, ethnic status
and education appeared to be the strongest factors. Those with higher education may be more mobile and harder
to reach while neglect of ethnic minorities has also been documented in other programs.
Conclusion: These findings can help managers of CDTI programmes to ensure ivermectin reaches all segments of
the population equally.
Background
The community directed treatment with ivermectin
(CDTI) programme of the African Programme for
Onchocerciasis Controls (APOC) was established in
1995. Its goal was to put in place a sustainable drug dis-
tribution system and maintain a minimum of 65%
annual population coverage with Mectizan
® in endemic
communities for at least 15 years, required for effective
control of onchocerciasis [1-4]. Currently, CDTI is on-
going in over 95,000 communities where over 98 million
ivermectin tablets are distributed annually to treat over
33 million people [5]
While reports of population coverage are encouraging
[5,6] coverage rates in a community may not give the
full picture of program success because there may be
individuals or groups who systematically do not comply
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disease transmission. Compliance, also known as adher-
ence, is defined as “the extent to which a patient acts in
accordance with the prescribed interval and dose of and
dosing regime [7]. Compliance with annual ivermectin
treatment therefore, has become a major challenge for
(APOC) as it enters its second decade of implementa-
tion on the ground. Considering that ivermectin treat-
ment will be needed for many years into the future, the
Technical Consultative Committee of APOC requested
a study to learn what factors might be associated with
compliance over time so that appropriate education and
intervention could be designed to help sustain annual
treatment [8].
To date, no published reports of CDTI have actually
determined whether individual community residents
actually comply with ivermectin treatment consistently
each year. This may be due in part to the fact that in
the early years of the program not enough annual distri-
butions had accumulated to provide a meaningful mea-
sure of compliance. Now that the original 25 projects,
which started in 1997-98, have been operating for
almost a decade annual compliance studies have become
possible. Such studies also are extremely desirable since
researchers are now pushing back the timeframe for
controlling onchocerciasis through annual ivermectin
dosing from 15 to 25 or more years [9]. APOC has a
mandate to establish within a period of 12 to 15 years,
effective and sustainable, community-directed treatment
with ivermectin throughout the endemic areas within
the geographic scope of the programme (APOC, 2006),
and thus requires a clear understanding of the long-
term compliance process in order to guide countries
toward sustainability.
There are studies about the factors that encourage or
discourage taking ivermectin during specific distribu-
tions such as age, gender and ethnicity [10-16]. Social
support and drug perceptions are other factors that
have influenced coverage, and hence may impact on
compliance [17]. Akogun et al. (2000) discussed the
importance of perceived benefits of ivermectin treat-
ment, which could be another motivating factor in
annual compliance [18]. These factors may or may not
explain long term compliance. APOC therefore wanted
a scientific basis to frame health education and commu-
nication that will promote continued compliance with
CDTI.
Compliance studies on other medical conditions have
shown that adhering to a medical regimen may be influ-
enced by the characteristics of the patient/client and
provider as well as the nature of the regimen and may
guide thinking about compliance with ivermectin treat-
ment. Considering the question of whether specific seg-
ments of the population may be systematically not
complying, one notes that ethnic origin and educational
level have been associated with compliance [19,20].
The study of compliance rates was explored in five
CDTI projects in two countries, Nigeria and Cameroon,
where annual ivermectin distribution had happened at
least eight times. This paper documents the compliance
rate among villagers who were old enough to begin iver-
mectin treatment at the start of these projects and some
of the possible socio-demographic characteristics asso-
ciated with compliance levels. Results are expected to
contribute to developing a simple and efficient protocol
for determining compliance rate at regular intervals,
which could be used by National Onchocerciasis Task-
forces for periodic monitoring of compliance to treat-
ment with ivermectin in their respective project areas.
Methods
Study Design and Area
The study was designed to determine rates of compli-
ance to and perceived benefits of annual ivermectin
treatment for the control of onchocerciasis in five
APOC supported project sites in Cameroon and Nigeria.
The cross-sectional approach was adopted in collecting
quantitative and qualitative data in study sites, which
had been screened through the feasibility study con-
ducted in 2005 that verified the availability of village
based adequate records to document eight continuous
years of ivermectin distribution. The five sites included
Kaduna, Cross River, Imo and Taraba States in Nigeria
and the Southwest Province in Cameroon, places where
CDTI projects have been providing ivermectin annually
since 1998.
Study Population and Sampling
The study population resided in villages where ivermec-
tin distribution has occurred using the CDTI approach
for at least eight consecutive years. The survey focused
on household members in these villages who were old
enough to have started receiving ivermectin at the
beginning of the program. At each site researchers bal-
loted for 2 districts among those that were found to
have adequate opportunity for longer-term compliance
resulting in a random sample of 10 villages per district.
The first step on reaching a village was obtaining and
reviewing the village distribution records. Village records
yielded data on whether distribution took place, the
level of coverage each year and the number of times
individual household members took ivermectin. Records
were also studied to determine whether there had been
continuous annual ivermectin distribution for eight
years. If this was not the case, another village was
sampled as a substitute.
Households ranged from 5-6 people in the rural areas
covered. A goal of 300 households was chosen per study
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were used to identify and ballot for 15 households in
each village. All resident household members included
in the household survey form.
The sample population for the qualitative component
consisted of community leaders, Community Directed
Distributors (CDDs: volunteers chosen by their commu-
nities), and health workers for in-depth interviews,
female and male adults, youth and ethnic minority com-
munity members who were included in focus group
discussions.
Data Collection and Management
The household survey form was adapted from the stan-
dard household coverage forms used in CDTI program
assessments by APOC. All selected households were vis-
ited and the purpose of the survey was explained to all
members present. Their permission was obtained to con-
tinue with the survey. Those present were asked to name
all currently resident household members and validate
their age, sex, educational and ethnic characteristics. They
were also asked about reasons any member did not take
ivermectin during the most recent distribution and to esti-
mate how many times each member had taken annual
ivermectin treatment in all previous distributions. Once all
information had been obtained in the household, the
researchers returned to the CDD and filled in a column
on the form for the number of times each household
member was recorded as having taken ivermectin in the
village register. Treatment data from the registers was
used for analysis of compliance rates to avoid recall bias.
Qualitative instruments consisted of in-depth inter-
view guides for village leaders, CDDs and health staff at
the nearest health facility. Twenty focus group discus-
sions were held in each site. These were divided among
male and female adults, youth and ethnic minorities and
between the two sample districts. The population used
for FGDs was alternated among the selected villages
such that only one FGD was held in each village
One hundred focus group discussions (FGDs) were
held. In-depth interviews took palce with 150 commu-
nity leaders, 100 CDDs as well as 10 health workers at
each site. Finally, field notes compiled by research staff
on a daily basis also provided the context of the infor-
mation gathered for the study.
All quantitative data were processed and analyzed with
the EPI INFO version 6d. Standard data entry templates
were prepared for all quantitative data collection instru-
ments. Simple descriptive statistics were employed in
characterizing the respondents while some socio-demo-
graphic and key perceptual factors were employed in
regression models constructed to explain levels of com-
pliance among the respondents.
All qualitative data transcripts were typed using stan-
dard word processing software. A computer-assisted
analysis of these data was undertaken using ATLAS.ti.
Illustrative quotes were extracted from coded domains
to explain the results of the quantitative analysis.
Researchers from all sites participated in a final data
analysis workshop.
Ethical Considerations
Ethical clearance was obtained from ethical clearance
committees of the University Teaching Hospitals in
Enugu, Kaduna in Nigeria and Buea in Cameroon. Per-
missions were also sought from the community leaders.
An informed verbal consent was obtained from every
eligible individual before inclusion into the study by
explaining the objective of the research. Privacy and
confidentiality were ensured.
After the interview, data collectors provided important
information regarding onchocerciasis mainly focusing on
misperceptions and knowledge deficits observed during
the interview with the respondents.
Results
Coverage data were obtained from the 101 selected vil-
lages to ascertain that distribution had taken place. A
brief look at the three years prior to the study is instruc-
tive. Mean population coverage rates were 70% in 2003,
70% in 2004 and 74% in 2005. The proportion of vil-
lages achieving the targeted 65% coverage in those years
was 65%, 67% and 78% respectively.
Overview of Household Survey
Among the 10,088 persons recorded on the household
survey forms, 23.9% came from Cameroon, and 76.1%
from Nigeria. Those above 9 years of age comprised
8,606 or 85.3% of the total, and this number became the
total used in further analysis. Among those above 9
years of age the portion of females was 50.7%. The sam-
ple was nearly equally divided between currently and
ever-married people (43.1%) and single ones (56.9%).
The majority (95.4%) reported observance of the Chris-
tian faith, 3.0% were Muslim, while 1.6% claimed indi-
genous African and other religious practices. The
smallest proportion of respondents (13.9%) had no for-
mal education, most had either primary (53.1%) or post-
primary (33.0%) education. Finally, 5.0% of this sample
was ethnic minorities.
Of this sample 80.7% had swallowed ivermectin tablets
during the last treatment round. Most (94.0%) could
recall a number of times ever taken, which ranged from
0 to 8 with an average of 4.6. The number of times
treatment was received according to CDD ranged from
0 to 8 with a mean of 4.1.
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treatments received as that recorded in the register.
Some (16.2%) thought they had taken ivermectin more
times, while another 16.2% recalled fewer treatments
than were recorded. This difference between recall and
records, was also found in the feasibility study, and
prompted the researchers to use CDD records as the
standard for calculating compliance.
Nearly 5,700 people mentioned reasons for not taking
tablets at some point in the past. These included the
usual exclusion criteria such as sickness (6.3%), preg-
nancy (8.8%), age (8.6%), and shortness (1.1%). Personal
reasons included bring absent (57.9%), fear of side
effects (1.8%), ‘do not take western drugs’ (0.1%), and
refusal (20.5%). Programmatic problems included not
being informed (4.4%), the drug had finished (1.0%), and
no distribution (9.2%).
Figure 1 shows the distribution of compliance over
eight distributions. At the lower end, 26.7% had taken
ivermectin only once, twice or not at all. A little less
than one-third (30.5%) were in the middle range, having
taken it 3-5 times. The largest number (42.9%) took
ivermectin 6-8 times (defined as ‘high compliance’).
Compliance Analysis
Table 1 is a contingency table showing the comparison
of socio-demographic factors with the three levels of
compliance. Among females 41.1% were in the high
compliance groups compared with 44.7% of males. Per-
sons aged 25 years and older (adult) had a greater pro-
portion of high compliers (47.4%) than the youth
(37.1%). In a similar vein, 49.0% of those who had ever
been married were high compliers compared with 36.8%
of single people. Although Christians (95.4%) comprised
the vast majority in the study area, only 41.8% were
high compliers compared to 66.2% of those adhering to
other religions.
Levels of high compliance decreased as educational
level rose: 59.7% with no formal education had high
compliance compared to 41.7% of those with at least
primary education and 37.6% of those with secondary or
higher education. Finally the proportion of high com-
pliers among ethnic minorities in the study areas was
much lower (13.3%) than that of the majority groups
(44.4%).
Further analysis was done using compliance as a
numerical value. Regression analysis confirmed the
bivariate analysis as seen in Table 2. Males, adults and
those who had ever been married had higher rates of
compliance than females, youth and singles. Education
level and Christianity were negatively associated with
compliance, while belonging to the majority ethnic
group in the area was a positive factor concerning com-
pliance rate. Although educational level and ethnic sta-
tus appear to be the strongest factors associated with
compliance, overall these various socio-demographic
variables explain only about eight percent of the var-
iance in compliance rate.
Perspectives from Qualitative Interviews
Qualitative results were in large part normative and sup-
ported the idea that all eligible people in the community
do take ivermectin regardless of their personal characteris-
tics. In Nigeria male and female community leaders and
CDDs agree that ‘men, women and children take it’.
Respondents explained that those who do not take it are
pregnant women and children below the age of 5 years (i.
e. only those not eligible). For example, in Taraba, Nigeria
FGD participants said all eligible people take the drug;
only those who are sick or below the age or height, as well
as pregnant women are not given. In Cameroon CDDs
also reported that those who take ivermectin are not sick,
not pregnant and are above 5 years of age (all eligible).
There was some disagreement on sex differences. “I
think men take it more regularly than women,” said a
FGD respondent in Cameroon). “Statistics shows that
when distribution is done during the farming period,
men take Mectizan
® more than women. Women are
more afraid than men,” was the observation of a Health
Worker in Cameroon.
The age factor was also discussed. Some respondents
support the idea that the elderly are more compliant.
Cameroon FGD participants felt that old people like to
take it more than younger because “they experience the
problem of blindness.” A female health worker in Imo
State, Nigeria observed that mostly elderly people take it
because “they are more in the village and know what
the drug will do.” In Taraba State, Nigeria a community
leader reported that, “While everyone wants to take
ivermectin, old people want it more.”
A view from youth in Cameroon is that youth take it
m o r eb e c a u s et h e ya r e“better informed,” and “it gives
them strength for more work.” A youth in Cross River
State, Nigeria said, “They (youth) go for it more, as they
have fewer side effects than the elderly.”
Figure 1: CDTI Compliance Rates
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Figure 1 CDTI Compliance Rates.
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ences. Male FGD participants in Cross River and in Imo
believe “everybody takes it if eligible, as it is good for
everybody.” In Kaduna a FGD participant thought that,
“Anyone who was not pregnant or too short, take iver-
mectin, even the elderly.”
Some occupational links were observed in the qualita-
tive data. On the positive side, after taking the drug, “...
farmers can go to their farms and work very well and
produce crops” (Nigeria). A contrasting view was that,
“Farmers may be weakened immediately they finish tak-
ing the drug because the drug makes you weak”
(Cameroon). Disruption of work itself, not the drug was
cited in another FGD where respondents noted that,
“Others prefer to go for business or the farm than stay
at home to collect the drug” (Nigeria).
While high compliance varies by ethnic status from
the household survey, most discussants claimed there
was no discrimination in providing ivermectin to minor-
ity groups. CDDs in Cameroon say they do not discrimi-
nate against ‘strangers’ living among them. A CDD in
Kaduna noted Fulani living among them who take iver-
mectin because of health education. Another CDD in
Kaduna confirmed that minority Fulani take it regularly
because of health education. A third Kaduna CDD
reported that minorities from other states take it
because they see us doing so. In an FGD among minor-
ity Fulani in Kaduna participants said they receive iver-
mectin the same as the indigenous people.
Some minority issues did arise that could affect com-
pliance. On a somewhat lighthearted note, a Kaduna
CDD said, “Igbos also take it, but read the label first.” A
Table 2 Analysis of Factors Associated with Compliance Rate
Correlation coefficient: r^2 = 0.08 ra^2 = 0.08
Source df Sum of Squares Mean Square F-statistic
Regression 6 4078.0842 679.6807 119.17
Residuals 8371 47743.9857 5.7035 .
Total 8377 51822.0698
B Coefficients
B 95% confidence Partial
Variable Mean coefficient Lower Upper Std Error F-test
SEX 0.4930 0.2370708 0.132312 0.341829 0.053441 19.6795
AGE 30.9842 0.0105952 0.006414 0.014776 0.002133 24.6773
EVERMAR 0.5010 0.2147027 0.075348 0.354057 0.071089 9.1216
CHRISTIAN 0.9550 -1.1844426 -1.434186 -0.934699 0.127402 86.4327
EDUCATION 1.2613 -0.4355129 -0.512785 -0.358240 0.039419 122.0646
ETHNIC 0.9481 2.0099674 1.778477 2.241458 0.118090 289.7001
Y-Intercept 3.7916014
Table 1 Demographic Factors and Compliance from Household Survey
Factor Number Level of Compliance (%) X
2, p value
Low
(0-2)
Moderate
(3-5)
High
(6-8)
Sex Male 4173 25.9 29.4 44.7 10.00
Female 4296 27.4 31.4 41.1 0.004
Age Youth (10-24 yrs) 3714 29.1 33.8 37.1 91.20
Adult 4766 24.8 27.8 47.4 0.000000
Ever Married Yes 4239 23.8 27.2 49.0 130.01
No 4228 29.6 33.6 36.8 0.000000
Religion Christian 8080 27.2 31.0 41.8 91.88
Others 391 14.1 19.7 66.2 0.000000
Education None 1395 17.8 22.4 59.7 208.36
Primary 3506 26.6 31.7 41.7 0.000000
Post-Primary 3565 30.1 32.3 37.6
Ethnic Majority 7984 24.5 31.1 44.4 380.14
Minority 435 66.4 20.2 13.3 0.000000
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welcome to it,” but noted that, “M i g r a n tf a r ml a b o r e r s
don’t want it as may make them miss work.” In Taraba,
a Fulani woman explained that they take ivermectin
only when it is brought to them (the program has not
trained minority CDDs). A female health worker in Tar-
aba observed that the main indigenous population
“takes it more.”
According to an FGD participant in Cross River ‘tra-
velers’ do not want to take ivermectin as it may hamper
their business. A Cross River CDD said minorities don’t
take it because they don’t know when it is being distrib-
uted. A CDD in Cameroon said seasonal farmers only
take it if the distribution period meets them while in the
community. A Kaduna community leader explained that
minorities do take the drug ‘when they are around’ One
villager was not complimentary when saying, “Those
who don’t take the drug regularly are the Fulani because
they are ignorant.”
Discussion
On average most of the villages have been obtaining
population treatment targets of 65% and above in recent
years, but that does not mean that individuals have been
complying with annual treatment. Over one-quarter of
age-eligible people in the community are low compliers
and thus serve as a reservoir for continued transmission
of onchocerciasis. The results of this study may help
CDTI program managers target segments of the popula-
tion with health education to increase compliance. Parti-
cularly, annual refresher training may be needed for
CDDs to review with them compliance problems and
encourage them to reach out to community members
with low levels of compliance.
An important caveat should be considered, and this is
the fact that these six socio-demographic factors explain
a small proportion of the overall variance in compliance
rates. Perceptual factors that may influence compliance
are being explored in another component of this study.
In terms of coverage, other studies have shown a per-
sistent difference between males and females. Even after
controlling for the exclusion criteria of pregnancy, it has
been found that women are less likely to take ivermectin
at a given distribution [10,11]. What may happen is that
if they are excluded once for pregnancy, they may be
less likely to take ivermectin again the next year [11].
Ethnic minority status is relative. Another coverage sur-
vey found that minorities living in their own villages
were more likely to take ivermectin during a distribution
than minorities living within villages of the dominant
ethnic group in the area [10].
Greater mobility may lie at the heart of three factors
associated with low compliance. Younger people, those
not yet married and those with higher education are
likely to travel outside the village for work and other
opportunities and miss annual distributions.
Conclusion
Future research could test the effect of educational
interventions on complian c en o wt h a tab a s e l i n eo f
compliance exists as a result of this study. Another pos-
sible study would compare compliance with microfilaria
levels. There has always been the assumption that
annual treatment is the ideal, but in fact studies linking
compliance and microfilaria levels might show that less
frequent treatment may still be somewhat beneficial in
terms of controlling transmission. Since CDTI will
hopefully continue into the future, continued health
education, program monitoring and operations research
will be essential for sustaining high levels of both cover-
age and annual compliance.
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